These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 34410534)

  • 1. Batch Selection via In Vitro/In Vivo Correlation in Pharmacokinetic Bioequivalence Testing.
    Burmeister Getz E; Carroll KJ; Mielke J; Jones B; Benet LZ
    AAPS PharmSciTech; 2021 Aug; 22(7):224. PubMed ID: 34410534
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of Multiple-Batch Approaches to Pharmacokinetic Bioequivalence Testing for Orally Inhaled Drug Products with Batch-to-Batch Variability.
    Burmeister Getz E; Carroll KJ; Christopher JD; Morgan B; Haughie S; Cavecchi A; Wiggenhorn C; Beresford H; Strickland H; Lyapustina S
    AAPS PharmSciTech; 2021 Aug; 22(7):225. PubMed ID: 34410557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Between-Batch Pharmacokinetic Variability Inflates Type I Error Rate in Conventional Bioequivalence Trials: A Randomized Advair Diskus Clinical Trial.
    Burmeister Getz E; Carroll KJ; Mielke J; Benet LZ; Jones B
    Clin Pharmacol Ther; 2017 Mar; 101(3):331-340. PubMed ID: 27727445
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bioequivalence between innovator and generic tacrolimus in liver and kidney transplant recipients: A randomized, crossover clinical trial.
    Alloway RR; Vinks AA; Fukuda T; Mizuno T; King EC; Zou Y; Jiang W; Woodle ES; Tremblay S; Klawitter J; Klawitter J; Christians U
    PLoS Med; 2017 Nov; 14(11):e1002428. PubMed ID: 29135993
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Between-Batch Bioequivalence (BBE): a Statistical Test to Evaluate In Vitro Bioequivalence Considering the Between-Batch Variability.
    Bodin J; Liandrat S; Kocevar G; Petitcolas C
    AAPS J; 2020 Sep; 22(5):119. PubMed ID: 32910283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Batch-to-batch pharmacokinetic variability confounds current bioequivalence regulations: A dry powder inhaler randomized clinical trial.
    Burmeister Getz E; Carroll KJ; Jones B; Benet LZ
    Clin Pharmacol Ther; 2016 Sep; 100(3):223-31. PubMed ID: 27037630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [In vivo verification of in vitro release specifications of a theophylline sustained-release preparation].
    von Nieciecki A; Fuchs WS; Pabst G; Müller M; Dilger C; Gay S; Laicher A; Stanislaus F
    Arzneimittelforschung; 1998 May; 48(5A):580-3. PubMed ID: 9676348
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Performance of the Population Bioequivalence (PBE) Statistical Test with Impactor Sized Mass Data.
    Chen S; Morgan B; Beresford H; Burmeister Getz E; Christopher D; Långström G; Strickland H; Wiggenhorn C; Lyapustina S
    AAPS PharmSciTech; 2019 Aug; 20(7):296. PubMed ID: 31444601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Truncated areas under the curve in the assessment of pioglitazone bioequivalence. Data from a single-center, single-dose, randomized, open-label, 2-way cross-over bioequivalence study of two formulations of pioglitazone 45 mg tablets under fasting conditions.
    Almeida S; Filipe A; Neves R; Pinho C; Pedroso P; Castillo A; Trabelsi F
    Arzneimittelforschung; 2011; 61(1):32-9. PubMed ID: 21355444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioequivalence assessment of pharmaceutical aerosol products through IVIVC.
    Sandell D
    Adv Drug Deliv Rev; 2021 Sep; 176():113895. PubMed ID: 34329687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bioequivalence study of two different tablet formulations of donepezil using truncated areas under the curve. A single-center, single-dose, randomized, open-label, 2-way crossover study under fasting conditions.
    Almeida S; Filipe A; Neves R; Desjardins I; Shink E; Castillo A
    Arzneimittelforschung; 2010; 60(3):116-23. PubMed ID: 20422942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative assessment of the switchability of generic products.
    Karalis V; Bialer M; Macheras P
    Eur J Pharm Sci; 2013 Nov; 50(3-4):476-83. PubMed ID: 23981332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel approach to the specification of in-vitro dissolution boundaries based on regulatory requirements for bioequivalence.
    Steinijans VW; Dietrich R; Trautmann H; Sauter R; Benedikt G
    Arzneimittelforschung; 1988 Aug; 38(8A):1238-40. PubMed ID: 3190812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetic and Safety Comparison of Two Capecitabine Tablets in Patients with Colorectal or Breast Cancer Under Fed Conditions: A Multicenter, Randomized, Open-Label, Three-Period, and Reference-Replicated Crossover Study.
    Wang CJ; Li T; Lin PP; Tao Y; Jiang X; Li X; Wen Q; Cao Y
    Adv Ther; 2021 Sep; 38(9):4798-4814. PubMed ID: 34347254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The bioequivalence of two different batches of two nifedipine controlled-release preparations with deficient batch conformity in in vitro liberation studies].
    Theiss U; Gebhardt E; Müller J
    Arzneimittelforschung; 1992 May; 42(5):629-32. PubMed ID: 1530675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Model-based bioequivalence approach for sparse pharmacokinetic bioequivalence studies: Model selection or model averaging?
    Philipp M; Tessier A; Donnelly M; Fang L; Feng K; Zhao L; Grosser S; Sun G; Sun W; Mentré F; Bertrand J
    Stat Med; 2024 Aug; 43(18):3403-3416. PubMed ID: 38847215
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of the Population Bioequivalence (PBE) Statistical Test Using an IPAC-RS Database of Delivered Dose from Metered Dose Inhalers.
    Morgan B; Chen S; Christopher D; Långström G; Wiggenhorn C; Burmeister Getz E; Beresford H; Hoffelder T; Acerbi D; Andrews S; Berry M; Dey M; Joshi K; McKenry M; Pertile M; Strickland H; Wilcox D; Lyapustina S
    AAPS PharmSciTech; 2018 Apr; 19(3):1410-1425. PubMed ID: 29435904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of pharmacokinetic studies outcome for locally acting nasal sprays by using different in vitro methods.
    Sibinovska N; Božič D; Bošković Ribarski M; Kristan K
    Int J Pharm; 2021 May; 601():120569. PubMed ID: 33812972
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An iterative method to protect the type I error rate in bioequivalence studies under two-stage adaptive 2×2 crossover designs.
    Molins E; Labes D; Schütz H; Cobo E; Ocaña J
    Biom J; 2021 Jan; 63(1):122-133. PubMed ID: 33000873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence studies: biometrical concepts of alternative designs and pooled analysis.
    Zintzaras E; Bouka P
    Eur J Drug Metab Pharmacokinet; 1999; 24(3):225-32. PubMed ID: 10716060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.